Effect of Ranibizumab on Malignant Conjunctival Neoplasia

Inclusion Criteria: * Ability to provide written informed consent and comply with study assessments for the full duration of the study * Age \> 21 years * Tumors whose treatment with standard therapy would cause significant visual morbidity * Diagnosis of biopsy proven malignant conjunctival neoplasia and are * Recurrent disease * Multi-focal disease * Diffuse disease Exclusion Criteria: * Extension of tumor into eye or orbit. * Regional spread or metastatic disease * Pregnancy (positive pregnancy test) or lactation. * Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch. * Current infection or inflammation in either eye * Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated * Participation in another simultaneous medical investigation or trial